Cutera® Appoints Jeryl L. Hilleman to Board of Directors
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors
BRISBANE, Calif.–(BUSINESS WIRE)–CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl “Jeri” Hilleman will join its Board of Directors, effective July 12, 2024.
Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive toward profitability, and expand its market presence with AviClear and other flagship products.
“We are thrilled to welcome Jeri to our Board of Directors,” said Taylor Harris, CEO of Cutera. “Her deep understanding of the healthcare sector, combined with her financial acumen and operational insights, will be instrumental in guiding Cutera through our next phase of growth. Jeri’s expertise aligns perfectly with our commitment to delivering value to our shareholders and advancing our patient-focused and customer-centric mission within the medical aesthetics field.”
Ms. Hilleman brings extensive experience in life sciences, having served as a public company CFO for close to 20 years. Most recently, she was the Chief Financial Officer of Intersect ENT, Inc., a commercial drug delivery company focusing on patients with ear, nose and throat conditions. Prior to Intersect ENT, Ms. Hilleman served as Chief Financial Officer of other public healthcare companies including Ocera Therapeutics, Inc., a biopharmaceutical company; Amyris, Inc., a renewable products company; and Symyx Technologies, a life sciences automation company. Her leadership has been pivotal in multiple successful capital-raising events and M&A transactions.
Ms. Hilleman also brings significant corporate governance experience to the Cutera board. She has served as the Chair of the Board of Omada Health, as well as Chair of the Audit Committee of multiple companies, including NovoCure, Limited, Minerva Neurosciences, HilleVax, SI-Bone, and XenoPort. Ms. Hilleman received a B.A. in History from Brown University and an M.B.A. from the Wharton School at the University of Pennsylvania.
“I am excited to join Cutera’s Board at this dynamic time,” said Ms. Hilleman. “Cutera’s innovative products and strong market position offer tremendous potential. I look forward to working with the Board and management team to drive growth and profitability, enhance operational efficiency, and create long-term value for our investors.”
About Cutera, Inc.
Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera strives to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.
Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to, Cutera’s plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera’s actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.
All statements made in this release are made only as of the date set forth at the beginning of this release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera’s financial performance for the first quarter ended March 31, 2024, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
Contacts
Investor Relations Contact:
Shelby Eckerman, VP, Finance
IR@Cutera.com
